Chronopharmacology of antitumor effect induced by interferon-β in tumor-bearing mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 294, Issue 2, 2000, Pages 746-752

  Takane, Hiroshi ^a   Ohdo, Shigehiro ^a   Yamada, Tomoko ^a   Yukawa, Eiji ^a   Higuchi, Shun ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; DNA; INTERFERON RECEPTOR; PROTEIN P21; PROTEIN P53; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; CHRONOPHARMACOLOGY; CONTROLLED STUDY; DNA SYNTHESIS; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; LIGHT DARK CYCLE; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; CIRCADIAN RHYTHM; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 0033929437     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Aschoff J (1963) Comparative physiology: Diurnal rhythms. Annu Rev Physiol 25: 581-600.
2. Baron S, Tyring S, Fleischmann WR, Coppenhaver DH, Niesel DW, Klimpel GR, Stanton GJ and Hughes K (1991) The interferons. J Am Med Assoc 266:1375-1383.
3. Beal SL and Sheiner LB, editors (1992) NONMEM User's Guides, NONMEM Project Group. University of California at San Francisco, San Francisco.
4. 125I-interferon alpha by isolated perfused rabbit kidney and liver. J Lab Clin Med 101:857-863.
5. Branca AA and Baglioni C (1981) Evidence that types I and II interferons have different receptors. Nature (Lond) 294:768-770.
6. WAF1/CIP1 mediated by STAT1. Science (Wash DC) 272:719-722.
7. Darnell JE Jr, Kerr IM and Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (Wash DC) 264:1415-1421.
8. Gomi K, Kimura H, Okabe M, Oka T and Morimoto M (1986) Synergistic anticellular and antiviral activities of human recombinant interferon-γ and β. J Pharmacobio-Dyn 9:871-878.
9. Gomi K, Morimoto M and Nakamizo N (1983) Growth-inhibitory activity of recombinant human interferon-β against cultured human cells. Gann 74:737-742.
10. Hori K, Zhang QH, Li HC and Saito S (1995) Variation of growth rate of a rat tumour during a light-dark cycle: Correlation with circadian fluctuations in tumour blood flow. Br J Cancer 71:1163-1168.
11. Hrushesky WJM (1985) Circadian timing of cancer chemotherapy. Science (Wash DC) 228:73-75.
12. Hunter T and Pines J (1994) Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 79:573-582.
13. Ida N, Uenishi N, Kajita A and Satoh Y (1982) Antitumor effect of human fibroblast interferon on the growth of human melanoma cells implanted in nude mice. Gann 73:952-960.
14. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y and Sugiyama Y (1997) Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther 283:520-527.
15. Koren S and Fleischmann WR (1993) Circadian variations in myelosuppressive activity of interferon-α in mice: Identification of an optimal treatment time associated with reduced myelosuppressive activity. Exp Hematol 21:552-559.
16. Koren S, Whorton EB and Fleischmann WR (1993) Circadian dependence of interferon antitumor activity in mice. J Natl Cancer Inst 85:1927-1932.
17. Koyanagi S, Ohdo S, Yukawa E and Higuchi S (1997) Chronopharmacological study of interferon-α in mice. J Pharmacol Exp Ther 283:259-264.
18. Kumar R, Korutla L and Zhang K (1994) Cell cycle-dependent modulation of α-interferon-inducible gene expression and activation of signaling components in Daudi cells. J Biol Chem 269:25437-25441.
19. Kushnaryov VM, MacDonald HS, Sedmak JJ and Grossberg SE (1985) Murine interferon-β receptor-mediated endocytosis and nuclear membrane binding. Proc Natl Acad Sci USA 82:3281-3285.
20. Kuwabara T, Kato Y, Kobayashi S, Suzuki H and Sugiyama (1994) Nonlinear pharmacokinetics of a recombinant human granulocyte colony-stimulating factor derivative (nartograstim): Species differences among rats, monkeys and humans. J Pharmacol Exp Ther 271:1535-1543.
21. Labrecque G, Bélanger PM, Doré F and Lalande M (1988) 24-Hour variations in the distribution of labeled microspheres to the intestine, liver and kidneys. Ann Rev Chronopharmacol 5:445-448.
22. Lau JYN, Sheron N, Morris AG, Bomford AB, Alexander GJM and Williams R (1991) Interferon-α receptor expression and regulation in chronic hepatitis B virus infection. Hepatology 13:332-338.
23. Levi F, Zidani R and Misset JL (1997) Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 350:681-686.
24. Levy DE, Kessler DS, Pine R and Darnell JE Jr (1989) Cytoplasmic activation of ISGF3, the positive regulator of interferon-α-stimulated transcription, reconstituted in vitro. Genes Dev 3:1362-1371.
25. Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK). Oncogene 16:217-225.
26. Ohdo S, Arata N, Furukubo T, Yukawa E, Higuchi S, Nakano S and Ogawa N (1998) Chronopharmacology of granulocyte colony-stimulating factor in mice. J Pharmacol Exp Ther 285:242-246.
27. Ohdo S, Grass GM and Lee VHL (1991) Improving the ocular to systemic ratio of topical timolol by varying the dosing time. Invest Ophthalmol Vis Sci 32:2790-2798.
28. Ohdo S, Koyanagi S, Yukawa E and Higuchi S (1997) Circadian rhythm of fever induced by interferon-α in mice. Life Sci 61:PL95-PL100.
29. Ohdo S, Nakano S and Ogawa N (1988) Chronopharmacological study of sodium valproate in mice: Dose-concentration-response relationship. Jpn J Pharmacol 47:11-19.
30. Ohdo S, Ogawa N, Nakano S and Higuchi S (1996) Influence of feeding schedule on the chronopharmacological aspects of sodium valproate in mice. J Pharmacol Exp Ther 278:74-81.
31. Qureshi SA, Salditt-Georgieff M and Darnell JE Jr (1995) Tyrosine-phosphorylated Stat1 and Stat2 plus a 48-kDa protein all contact DNA in forming interferon-stimulated-gene factor 3. Proc Natl Acad Sci USA 92:3829-3833.
32. Sangfelt O, Erickson S, Einhorn S and Grander D (1997) Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-α in hematopoietic cell lines. Oncogene 14:415-423.
33. Sun WH, Pabon C, Alsayed Y, Huang PP, Jandeska S, Uddin S, Platanias LC and Rosen ST (1998) Interferon-α resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood 91:570-576.
34. Tamura T, Matsuzaki M, Harada H, Ogawa K, Mohri H and Okubo T (1997) Upregulation of interferon-α receptor expression in hydroxyurea-treated leukemia cell lines. J Invest Med 45:160-167.
35. Thornton AM, Ogryzko VV, Dent A, Sharf R, Levi BZ, Kanno Y, Staudt LM, Howard BH and Ozato K (1996) A dominant negative mutant of an IFN regulatory factor family protein inhibits both type I and type II IFN-stimulated gene expression and antiproliferative activity of IFNs. J Immunol 157:5145-5154.
36. Watanabe H, Ohdo S, Ishikawa M and Ogawa N (1992) Effects of social isolation on pentobarbital activity in mice: Relationship to racemate levels and enantiomers levels in brain. J Pharmacol Exp Ther 263:1036-1045.
37. Wong VLY, Rieman DJ, Aronson L, Dalton BJ, Greig R and Anzano MA (1989) Growth-inhibitory activity of interferon-beta against human colorectal carcinoma cell lines. Int J Cancer 43:526-530.
38. Yamada H and Shimoyama M (1983) Growth inhibitory activity of human lymphoblastoid and fibroblast interferons in vitro. Gann 74:299-307.
39. Zoon KC and Arnheiter H (1984) Studies of the interferon receptors. Pharmacol Ther 24:259-278.